RBC Capital cuts Intra-Cellular stock rating, hikes target to $132
RBC Capital Markets adjusted its stance on Intra-Cellular Therapies shares, downgrading the biopharmaceutical company from Outperform to Sector Perform. The firm, however, raised its price target on ...
Business Insider3y
Buy these 4 stocks poised benefit from a spike in silver prices, says RBC Capital Markets — including 2 set to soar 73%
"Prices have moved up nearly 16% since Thursday with no 'normal' reasons that could justify this price action," Tyler Broda, an RBC Capital Markets analyst, said in a February 1 research note.